Scum map locations 20213/23/2023 Operating cash flow was $2.7 million quarter ending cash was $87.8 million after a $4.3 million payment for acquisition-related contingent consideration, with no outstanding debt.ġ OA Pain Management was previously referred to as Joint Pain Management Non-Orthopedic was previously referred to as Other.Ģ See description of non-GAAP financial information contained in this release. Adjusted net loss 2 was ($0.7) million, or ($0.05) per share, compared to adjusted net income 2 of $0.8 million, or $0.05 per diluted share, in the prior year.Īdjusted EBITDA 2 was $4.1 million, compared to adjusted EBITDA 2 of $5.7 million in the prior year. Net loss was ($4.2) million, or ($0.29) per share, compared to net income of $0.6 million, or $0.04 per diluted share, in the prior year. Gross margin was 57%, including $1.6 million of non-cash acquisition-related expenses and $2.6 million product rationalization charges Adjusted gross margin 2 was 67%. Non-Orthopedic 1 revenue of $2.8 million, up 27% Joint Preservation and Restoration revenue of $11.8 million, up 6% OA Pain Management 1 revenue of $25.7 million, down 2% Revenue in the third quarter of 2022 was $40.3 million, up 2% compared with $39.5 million in the third quarter of 2021. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today reported financial results for its third quarter ended September 30, 2022. 08, 2022 (GLOBE NEWSWIRE) - Anika Therapeutics, Inc. On Track to Achieve Stated FY2022 GuidanceīEDFORD, Mass., Nov. Positive Feedback from Limited Market Release of New X-Twist™ Fixation System for Soft Tissue Repair On Track for Full Market Release in Early 2023
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |